Crohn Disease (CD)Up4-CDNCT07884045
Impact of Ultra-Processed Food Reduction on Remission Duration in Pediatric Crohn's Disease
A study testing Ultra-Processed Food Reduction Counseling and Standard Dietary Counseling in people with Crohn Disease (CD), run by University Hospital, Motol at 2 sites in Czechia.
Trial summary
Crohn's disease is a chronic inflammatory bowel disease. This study will investigate whether reducing the intake of ultra-processed foods through regular consultations with a registered dietitian can help children and adolescents with Crohn's disease stay in remission for longer. Read more about this study
- Who is it for?
- Ages 10 to 18 years
- Conditions the study is for
- Crohn Disease (CD)
- What is being tested?
- Ultra-Processed Food Reduction Counseling and Standard Dietary Counseling
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 124 participants
- Where
- 2 sitesCzechia
- Study dates
- 1 Aug 2026to 31 Dec 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Children and adolescents aged 10 to 18 years (inclusive).
- Diagnosis of Crohn's disease.
- Clinical remission (MINI score <8) maintained for at least 3 months before randomization.
- Ability of the participant and parent/legal guardian to provide informed consent/assent according to local regulations.
Who cannot join
- Stoma or previous colectomy.
- Pregnancy.
- Exclusive enteral nutrition (EEN), Crohn's Disease Exclusion Diet (CDED), Healthy \& Tasty diet, parenteral nutrition, or other major self-imposed dietary restrictions (including vegan or vegetarian diets) at the start of the intervention. - Partial enteral nutrition and self-modified partial CDED or Healthy \& Tasty diets are permitted.
- Eating disorder.
- Change in Crohn's disease therapy without prior achievement of clinical remission (MINI score <8).
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Czechia2 sites, 2 recruiting
- Not yet recruiting
Department of Paediatric Gastroenterology, University Hospital Motol and Homolka
Prague
- Recruiting
University Hospital Motol and Homolka
Prague
About this study
Official title: Impact of Ultra-Processed Food Reduction on Remission Duration in Paediatric Patients With Crohn's Disease
Crohn's disease is a chronic inflammatory bowel disease. This study will investigate whether reducing the intake of ultra-processed foods through regular consultations with a registered dietitian can help children and adolescents with Crohn's disease stay in remission for longer. Participants will be randomly assigned to either an intervention group receiving guidance on reducing ultra-processed foods or a control group receiving standard healthy eating advice. The study will also evaluate the safety, nutritional adequacy, growth, and quality of the dietary intervention.
Read the detailed description
Crohn's disease (CD) is a chronic inflammatory bowel disease that often begins during childhood or adolescence and requires lifelong treatment. While pharmacological therapies are effective in inducing and maintaining remission, dietary factors are increasingly recognized as important modifiers of disease activity. Exclusive enteral nutrition and several whole-food dietary approaches have demonstrated that nutrition can influence intestinal inflammation. Observational studies have also reported that higher consumption of ultra-processed foods is associated with an increased risk of Crohn's disease, greater disease activity, and a higher risk of relapse. However, no randomized controlled trial has evaluated whether reducing ultra-processed food intake can prolong remission in pediatric patients with Crohn's disease.
The objective of this randomized controlled trial is to determine whether regular dietary counseling aimed at reducing the consumption of ultra-processed foods can prolong remission in children and adolescents with Crohn's disease receiving standard medical care. The intervention is designed to support gradual and sustainable dietary changes rather than short-term restrictive dieting, with the goal of increasing the proportion of minimally processed foods (NOVA category 1) in the habitual diet while maintaining adequate nutritional intake and normal growth.
Participants aged 10-18 years with Crohn's disease who have maintained clinical remission for at least three months will be randomly assigned in a 1:1 ratio to either the intervention or the control group. Both groups will receive the same number of consultations with a registered dietitian throughout the 12-month study period. In the intervention group, consultations will focus on identifying major sources of ultra-processed foods and supporting families in reducing their consumption using individualized, practical strategies. The control group will receive standard dietary counseling focused on healthy eating without specific recommendations regarding ultra-processed food intake. This design allows the effect of reducing ultra-processed foods to be evaluated while minimizing differences in participant contact and attention between study groups.
Participants will be followed for 12 months during routine outpatient visits. At each study visit, information on disease activity, medical treatment, anthropometric measurements, laboratory parameters, and dietary intake will be collected. Intake of ultra-processed foods will be assessed using a modified version of the validated Processed Food Questionnaire (PFQ), adapted for the pediatric population and Czech dietary habits. Adherence to the intervention will also be evaluated using a dedicated questionnaire.
The primary objective is to evaluate whether the intervention increases the proportion of patients who remain in clinical remission after 12 months. Secondary objectives include evaluation of time to relapse, the association between the magnitude of reduction in ultra-processed food intake and clinical outcomes, and assessment of the safety of the intervention. Particular attention will be paid to growth, nutritional status, iron status, albumin concentrations, and other adverse events to ensure that dietary modification does not compromise nutritional adequacy in this pediatric population.
If successful, this study will provide the first randomized evidence regarding whether reduction of ultra-processed food consumption can improve long-term outcomes in pediatric Crohn's disease. The findings may inform future dietary recommendations and provide an evidence-based, non-pharmacological strategy to complement standard medical therapy in maintaining remission.
- Conditions
- Crohn Disease (CD)
- Being tested
- Ultra-Processed Food Reduction Counseling, Standard Dietary Counseling
- Keywords
- Crohn Disease, Ultra-Processed Foods, Pediatric Crohn Disease, Dietary Intervention
- Medical subject headings
- Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultra-Processed Food Reduction CounselingBehavioural
Individual dietary counseling delivered by a registered dietitian to reduce consumption of ultra-processed foods (NOVA category 4) and increase intake of minimally processed foods while maintaining nutritional adequacy and normal growth. Consultations are provided at baseline, week 1, and months 3, 6, and 9, with continued support through month 12.
Standard Dietary CounselingBehavioural
Individual dietary counseling delivered by a registered dietitian focusing on a balanced diet and healthy eating habits without specific advice to reduce ultra-processed food intake. Consultations are provided on the same schedule as the intervention group.
| Study group | Role | What they receive |
|---|---|---|
| Ultra-Processed Food Reduction | Experimental | Participants receive structured dietary counseling from a registered dietitian aimed at reducing ultra-processed food intake while maintaining adequate nutritional intake and normal growth. Counseling is provided over a 12-month period in addition to standard medical care. Receives: Behavioral: Ultra-Processed Food Reduction Counseling |
| Standard Dietary Counseling | Active comparator | Participants receive structured dietary counseling focused on healthy eating without specific recommendations to reduce ultra-processed food intake. The frequency and duration of counseling are identical to the intervention group. Receives: Behavioral: Standard Dietary Counseling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Participants Remaining in Clinical Remission at 12 Months
The primary endpoint is the proportion of participants without relapse 12 months after randomization. Relapse is defined as a MINI score ≥8 at any scheduled study visit during the 12-month follow-up (months 3, 6, 9, or 12). Participants who do not meet the relapse criterion are considered to have remained in clinical remission. The primary analysis will follow the intention-to-treat principle.
Measured: 12 months after randomization
Secondary outcomes (3)
Time to Relapse
Time from randomization to the first study visit at which relapse is identified. Relapse is defined as a MINI score ≥8. Participants without relapse will be censored at their last completed study visit.
Measured: Up to 12 months after randomization
Correlation Between Reduction in Ultra-Processed Food Intake and Relapse-Free Remission
Correlation between the change in ultra-processed food intake, assessed using the Processed Food Questionnaire (PFQ), and relapse-free remission at 12 months. Ultra-processed food intake will be measured using the PFQ, and relapse-free remission will be assessed using the MINI index, with relapse defined as a MINI score ≥8.
Measured: Baseline to 12 months
Correlation Between Reduction in Ultra-Processed Food Intake and Time to Relapse
Correlation between the change in ultra-processed food intake, assessed using the Processed Food Questionnaire (PFQ), and time to first relapse. Ultra-processed food intake will be measured using the PFQ, and time to relapse will be measured in months from baseline to the first occurrence of relapse, defined as a MINI score ≥8.
Measured: Baseline to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2026
- Study start1 Aug 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Crohn Disease (CD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized in a 1:1 ratio to either an intervention group receiving structured dietary counseling focused on reducing ultra-processed food intake or a control group receiving standard dietary counseling without specific guidance on ultra-processed foods. Randomization will be stratified according to treatment regimen and time since diagnosis using a minimization algorithm. Both groups will receive the same number and timing of consultations over the 12-month study period.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 124 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Motol
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tereza Lerchova, University Hospital, Motol
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07884045
- Sponsor's protocol ID
- GAUK322226
- Acronym
- Up4-CD
- Status last verified
- Oct 2026
- First submitted
- 24 Jul 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No